CD8A and cancer: Increasing the number of effective APCs at the tumour site would increase the potential for augmenting the immune response against cancer cells by cross-presentation of TAAs to CD8+ cells [261], and to shift the balance from immunosuppression to immune surveillance and elimination [4].